PMID- 10482982
OWN - NLM
STAT- MEDLINE
DCOM- 19990930
LR  - 20220309
IS  - 0887-6924 (Print)
IS  - 0887-6924 (Linking)
VI  - 13
IP  - 9
DP  - 1999 Sep
TI  - Incidence and clinical significance of 6q deletions in B cell chronic lymphocytic 
      leukemia.
PG  - 1331-4
AB  - Deletions affecting the long arm of chromosome 6 (6q) are among the most commonly 
      observed chromosomal aberrations in lymphoid malignancies and have been 
      identified as adverse prognostic factor in subsets of tumors. Whereas at least 
      two regions of minimal deletion have been established, one in 6q21-q23 and 
      another in 6q25-q27, no tumor suppressor gene that might be involved in the 
      pathogenesis of lymphoid malignancies has been so far identified from these 
      segments. For B cell chronic lymphocytic leukemia (B-CLL) conflicting data have 
      been reported regarding the incidence and prognostic significance of 6q 
      deletions. In the current study we have used two YAC clones mapping to deletion 
      regions in bands 6q21 and 6q27 as probes for fluorescence in situ hybridization 
      (FISH) in a large series of B-CLL cases to analyze the incidence, localization 
      and clinical significance of 6q aberrations. Among 285 patients with B-CLL 
      studied we identified 21 cases (7%) with 6q deletions. All deletions were found 
      with the probe mapping to 6q21 while the 6q27 region was deleted only in a third 
      of these cases. Analysis of the clinical characteristics and laboratory 
      parameters showed that the patients with 6q deletions had higher white blood cell 
      counts and more extensive lymphadenopathy. However, the overall survival and the 
      treatment-free intervals were similar in the two groups. We conclude that 
      deletions in 6q21 occur in 7% of B-CLL and identify a subgroup of patients 
      characterized by a larger tumor mass but no inferior outcome.
FAU - Stilgenbauer, S
AU  - Stilgenbauer S
AD  - Medizinische Klinik und Poliklinik V, University of Heidelberg, Germany.
FAU - Bullinger, L
AU  - Bullinger L
FAU - Benner, A
AU  - Benner A
FAU - Wildenberger, K
AU  - Wildenberger K
FAU - Bentz, M
AU  - Bentz M
FAU - Dohner, K
AU  - Dohner K
FAU - Ho, A D
AU  - Ho AD
FAU - Lichter, P
AU  - Lichter P
FAU - Dohner, H
AU  - Dohner H
LA  - eng
PT  - Clinical Trial
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
PL  - England
TA  - Leukemia
JT  - Leukemia
JID - 8704895
RN  - 0 (DNA Probes)
SB  - IM
MH  - *Chromosome Deletion
MH  - Chromosome Mapping
MH  - *Chromosomes, Human, Pair 6
MH  - DNA Probes
MH  - Female
MH  - Humans
MH  - In Situ Hybridization, Fluorescence
MH  - Incidence
MH  - Leukemia, Lymphocytic, Chronic, B-Cell/*genetics
MH  - Male
MH  - Middle Aged
MH  - Prognosis
EDAT- 1999/09/14 00:00
MHDA- 1999/09/14 00:01
CRDT- 1999/09/14 00:00
PHST- 1999/09/14 00:00 [pubmed]
PHST- 1999/09/14 00:01 [medline]
PHST- 1999/09/14 00:00 [entrez]
AID - 10.1038/sj.leu.2401499 [doi]
PST - ppublish
SO  - Leukemia. 1999 Sep;13(9):1331-4. doi: 10.1038/sj.leu.2401499.